Literature DB >> 17054675

CD34 stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies.

Claire Booth1, Jean-Antoine Ribeil, Françoise Audat, Liliane Dal-Cortivo, Paul A Veys, Adrian J Thrasher, E Graham Davies, François Lefrère, Alain Fischer, Marina Cavazzana-Calvo, H Bobby Gaspar.   

Abstract

Haematopoietic stem cell transplantation can be limited by ineffective haematopoiesis and poor immune recovery. A CD34(+) cell infusion without conditioning has the potential to improve stem cell function with limited toxicity. Eighteen patients with congenital immunodeficiencies received CD34(+) boosts for various defects. When given <1 year after the original graft, six of seven cytopenic patients achieved transfusion independence. A second cohort (n = 11) received boosts >1 year after the original graft; only minimal changes in immune function or chimaerism were noted. Unconditioned stem cell boosts have limited toxicity but should be given early after the original graft to be effective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054675     DOI: 10.1111/j.1365-2141.2006.06333.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Radiosensitive severe combined immunodeficiency disease.

Authors:  Christopher C Dvorak; Morton J Cowan
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

2.  Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.

Authors:  Linda M Griffith; Morton J Cowan; Donald B Kohn; Luigi D Notarangelo; Jennifer M Puck; Kirk R Schultz; Rebecca H Buckley; Mary Eapen; Naynesh R Kamani; Richard J O'Reilly; Robertson Parkman; Chaim M Roifman; Kathleen E Sullivan; Alexandra H Filipovich; Thomas A Fleisher; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2008-11-06       Impact factor: 10.793

3.  A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Authors:  Christopher C Dvorak; Biljana N Horn; Jennifer M Puck; Agnieszka Czechowicz; Judy A Shizuru; Rose M Ko; Morton J Cowan
Journal:  Pediatr Transplant       Date:  2014-06-30

4.  Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors.

Authors:  E Rådestad; H Wikell; M Engström; E Watz; B Sundberg; S Thunberg; M Uzunel; J Mattsson; M Uhlin
Journal:  J Immunol Res       Date:  2014-10-13       Impact factor: 4.818

5.  Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion.

Authors:  Emelie Rådestad; Mikael Sundin; Johan Törlén; Sarah Thunberg; Björn Önfelt; Per Ljungman; Emma Watz; Jonas Mattsson; Michael Uhlin
Journal:  Front Immunol       Date:  2019-02-11       Impact factor: 7.561

6.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

7.  Long-term outcome of non-ablative booster BMT in patients with SCID.

Authors:  C L Teigland; R E Parrott; R H Buckley
Journal:  Bone Marrow Transplant       Date:  2013-02-11       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.